Clinical Trials
30 trialsI-SPY
QuantumLeap Healthcare Collaborative
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
National Cancer Institute (NCI)
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
MC1079
Chinese University of Hong Kong
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
National Cancer Institute (NCI)
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
MK-2206 for Recurrent Malignant Glioma
Dana-Farber Cancer Institute
S1115
National Cancer Institute (NCI)
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Memorial Sloan Kettering Cancer Center
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
National Institutes of Health Clinical Center (CC)
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
AKTIL
Centre Leon Berard
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
National Cancer Institute (NCI)
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center